This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutInfliximabWhat is infliximabMechanism of actionBiosimilarsApprovalOverviewPosition statementsECCOEULARESPGHANDosing & SwitchingDosingIV dosingAdministration & storageIV administrationStorageSafety informationImportant safety informationSwitchingConsiderations for switchingSafety informationImportant safety informationSafety informationImportant safety informationClinical EvidenceRandomised controlled trial evidenceSummary: randomised controlled trial evidenceSupport & ResourcesMaterials
IV dosing

Dosing with INFLECTRA® (CT-P13*/infliximab) is individualised based on each adult or paediatric patient’s weight.1

  • Dose escalation or shortened dosing intervals may help regain or maintain clinical response in some patients with rheumatoid arthritis1

Please refer to the INFLECTRA® Summary of Product Characteristics for specific dosing recommendations

TitleINFLECTRA® is dosed identically to Remicade™†1,2

For full dosing information, access the INFLECTRA® Summary of Product Characteristics

CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA™.Remicade™ is a registered trademark of MSD.INFLECTRA® maintenance infusions are initiated on Dose 3 in patients with moderately to severely active Crohn’s disease. For all other indications, maintenance infusions are initiated on Dose 4.1INFLECTRA® maintenance infusions are given every 6-8 weeks in patients with ankylosing spondylitis. For all other indications, maintenance infusions are given every 8 weeks.1​​​​​​​IV, Intravenous.References:INFLECTRA® Summary of Product Characteristics.Remicade™ Summary of Product Characteristics.
Administration & Storage

Learn more about the IV administration of INFLECTRA®

 Read more Loading

Legal Category: S1A
Further information is available upon request

PP-IFA-IRL-0166 October 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0784. June 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0784. June 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0784. June 2024